Men with prostate cancer may be spared radiotherapy after surgery, according to late-breaking results of the RADICALS-RT trial presented by Parker et al at the European Society for Medical Oncology (ESMO) Congress 2019. The study answers a long-standing question about whether the benefits of radiotherapy after surgery outweigh the side effects.
The randomized, phase II ORIOLE trial studying the efficacy of targeted high-dose radiation for men with oligometastatic prostate cancer has shown that stereotactic ablative radiation (SABR) is an effective and safe option for patients who wish to delay hormone-suppression therapy. Data from the trial also showed radiation therapy can generate an immune system response not previously seen in oligometastatic prostate cancer. These findings were presented by Phillips et al at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO).
In a study reported in the Journal of Oncology Practice, Modi et al found that the difference in the rates of use of conservative management of prostate cancer widened between lower-use and higher-use urology practices between 2014 and 2018...
The terrorist attacks on September 11, 2001, on the World Trade Center in New York City resulted in the deaths of more than 2,700 people. Nearly 2 decades later, that number may soon be exceeded by the more than 2,000 deaths—and climbing—of first responders to the attack, including firefighters, police officers, paramedics, and military personnel, from a variety of cancers, such as prostate, head and neck, thyroid, and multiple myeloma.